The Carnage Continues: GlaxoSmithKline to Slash an Additional 4,000 Jobs
GlaxoSmithKline (GSK) Britain’s largest pharmaceutical company today announced it plans on slashing 4,000 jobs over the coming months. The bulk of the cuts will be in America and Europe, and are part of the company’s efforts to shift resources away from low-growth territories into parts of the world with greater scope to expand sales, most notably Asia. GSK’s currently employs 99,000 workers worldwide. The reduction in headcount will be combined with a drive to make the company’s research and development more cost-efficient.
While the job losses will not be as severe as those announced last week by its rival Astra Zeneca, they will provide further depressing news for a sector that is fighting to contain costs as it reduces its reliance on big-selling blockbuster drugs, many of whose patents will expire in the next two to three years.
The pipeline of new drugs at GSK is much deeper than at many of its rivals, say industry analysts. The company’s roster of planned launches includes Menhibrix, a vaccine to combat meningitis, and Benlysta (belimumab), a novel, monoclonal antibody treatment for systemic lupus erythematosus that it is co-developing with Maryland-based, Human Genome Sciences. In total, the group has more than 30 products in the advanced stages of development and testing.
While GSK continues to develop new drugs, it has increasingly been turning to emerging markets to find and sustain corporate growth. This has meant that thousands of jobs have already been sacrificed in the West, although the company is adding staff elsewhere. For example, it recently cut 2,000 sales jobs in America but added 1,500 staff in China. Also, GSK’s vaccine division has suffered a few regulatory setbacks with its pneumococcal vaccine Synflorix and its cervical cancer vaccine Cervarix. The loss of market share in these areas has put additional financial pressure on the company.
Like many of its competitors, GSK is looking to other divisions of the company to cover projected losses in the pharmaceutical sector. Recently, GSK has shifted a lot of its attention to its consumer products division, which owns brands such as Lucozade and Ribena soft drinks, Aquafresh and Sensodyne toothpaste, and over-the-counter medicines such as Panadol painkillers and Alli, a weight-loss pill. Analysts predict the division will have raised its annual sales 18% to £4.7 billion. A deal signed last year to increase sales of Lucozade in China has provided the blueprint for how the company would like to develop the consumer healthcare side of its business.
Similarly, last week, Sanofi-Aventis, a French rival, announced a joint venture with Minsheng Pharmaceutical Group, a Chinese company, to sell vitamin pills and nutritional supplements. Also, Pfizer recently announced it would bid for the possibility of purchasing the financially-troubled German generics manufacturer Ratiopharm; signaling the possibility that the world's largest branded pharmaceutical manager may be toying with the idea of getting into the generics business.
Late last year I predicted that more pharmaceutical company employees would loss their jobs. Sadly, this prediction has come true. That said, I am surprised at the scope and size of the layoffs that have already taken place in 2010. I suspect that more layoffs are likely in the near future if the economy doesn’t turn around anytime soon.
Hat tip to Ed at the Pharmalot blog!
Until next time...
Good Luck and Good Job Hunting (try medical devices or biotech)!!!!!!!!
.jpg)
I Am Biotech.jpg)
When I .jpg)
Theravance Inc. .jpg)
Have you ever found yourself in a situation where you needed important biological, genetic or other life sciences information quickly? Sure, you can Google the topic but it takes time to wade through all of the search results until you find the right one!.jpg)
It’s no secret that pharmaceutical and biotechnology companies are “not in love” with social media. However, whether life sciences company like it or not, social media is beginning to affect human clinical testing with an increasing number of patients demanding access to unapproved experimental drugs to treat life-threatening illnesses. 
, or 12 percent of its work force, by 2014 to cut costs as it reported disappointing fourth quarter earnings. The job cuts will be made across all regions and divisions and were necessary because some of the company’s major products including the child asthma medication Pulmicort, which made sales of $1.3 billion in 2009, and breast cancer treatment Arimidex, with $1.92 billion in sales will be losing patent protection in the near future.
While I never was involved in a corporate acquisition or merger, I have many friends who have lived through them and based on their experiences it is a never a “pretty sight.” Merger aftermaths usually feature massive layoffs, executive management disputes and turf wars and corporate culture clashes tha occur when two workforces are forced to merge as one. However, sometimes mergers may be a good thing for struggling companies. To that end, Pfizer .jpg)
Politicians, educators and business leaders love to complain about the America’s dwindling competitiveness in math and science and the growing lack of innovation that seems to be pervasive among many American high school and college-aged students. This is the same mantra that I have been hearing for the past 20 years. Unfortunately, while the powers at be like to complain about these things, no government agencies, educational groups or private sector businesses seem to be able to come up with approaches or solutions to these problems (talk about lack of innovation!). .jpg)
I previously have written about various aspects of the interviewing process in the life sciences industry. While I had written on various aspects of interviewing, I never assembled all of the pieces into a single post to give job seekers a complete view of the entire process. To that end, I came across a great post authored by 
.jpg)
The Pharmalot blog authored by the intrepid Ed Silverman .jpg)
Mark Senak, who authors the Eye on FDA blog, today posted a .jpg)
Let’s face it; scientists aren’t generally regarded as being funny. While I have met several very funny researchers during my almost 35 year career, the vast majority of my colleagues have been mostly serious and, at times, difficult to amuse; especially when things weren't going so well in the lab..jpg)
Harrison Ford’s new movie “Extraordinary Measures” (also starring Brendan Fraser) is loosely based on 
As many BioJobBlog readers may know by now, my
There is no question that job opportunities for recent life sciences undergraduates, graduate students and postdoctoral fellows are becoming increasingly difficult to find. While this is troubling, older, mid-career bioprofessionals who may be looking for new jobs and challenges are having a rougher go of it. This is because older employees generally cost more to hire and many employers mistakenly believe that seasoned employees make lack the drive and technological skills as compared with younger, less experienced jobseekers.(1).jpg)
Despite 
Pfizer 
. Teva Pharmaceutical Industries Ltd, the Swedish private equity fund EQT and Pfizer are the three finalists to purchase Ratiopharm GmbH which is valued at about €2.8-3 billion. The finalists will make their bids in early February. France’s Sanofi-Aventis SA Euronext and China’s Sinopharm Group Co. Ltd. withdrew from the tender in December.jpg)
Last week, the market-analyst firm 
I previously posted several articles on 
While Genzyme has begun to address its
Many progressives and left-leaning individuals (like me) voted for President Obama because he presented himself as somebody who will stand up for what he believes. Until recently, I, along with others, have been deeply disappointed in his performance and it was no longer clear to me what he truly believes in. However, his recent stand on healthcare reform (sadly without a public option), his performance at the global warming summit and most recently his quick response and unequivocal support for Haitian earthquake victims suggest to me that we are finally beginning to see what President Obama believes and what he is made up. To that end, Obama has 
Life sciences employers ranging from academic institution to private sector companies are increasingly turning to telephone interviews as an initial means to screen prospective job candidates. While in many instances these interviews are perfunctory, they are conducted for two main reasons. First, the employer wants to verify that the information presented by the candidate in his/her curriculum vitae is correct and accurate. Second, and perhaps more importantly, to determine whether or not a candidate has sufficient oral communications skills that warrant the cost necessary to bring a candidate in for a face-to-face on site interview. 
Ed Silverman, over at the newly reinvigorated Pharmalot Blog, .jpg)
It is getting difficult to keep track of the job cuts that are happening almost daily at Pfizer. A quick perusal of the job cuts to date indicate that the company has eliminated about 1200 jobs in the past week;
As Jonathan Richman, author of the Dose of Digital blog focused on pharmaceutical marketing aptly put it, its time to “stop talking about social media.” “.jpg)
I am frequently asked by graduate students and postdoctoral fellows who are having trouble finding a research and development job, whether or not it makes sense to go to business school to get an Masters of Business Administration) MBA degree to enhance their business acumen. While I don’t think it would hurt (especially if you are interested in business), I also don’t think most scientists benefit from enrolling traditional MBA degree programs. With this in mind, some forward-looking academic institutions have launched joint PhD-MBA programs which allow students enrolled in these programs to graduate with PhD and MBA degrees at the end of their graduate training..jpg)
Just when you thought that holding on to a job couldn’t get any worse, Pfizer 
As part of their licensure requirements, all physicians and other healthcare providers (HCPs) in the US must participate in continuing medical education (CME). CME requirements are established on a state-by-state basis HCPs who fail to meet annual quotas face reprimand, censure and possibly loss of their medical licenses. As you may imagine, CME is a big business and, not surprisingly, there is no dearth of CME content developers and providers. Unfortunately, CME course development costs are high and, despite state mandated licensure requirements, no one seems to want to sponsor or underwrite the CME development programs except drug and devices companies. Obviously, this creates the potential for monumental conflicts of interest mainly because physicians and other HCPs are drug and device company primary customers..jpg)
Just when you thought things couldn’t get much worse for New Jersey, Merck and Pfizer .jpg)
For many years, I taught medical students that the emergence of antibiotic resistant strains of bacteria primarily resulted from the overuse and misuse of antibiotics by physicians. While this seemed to make sense, I started chatting in the late 1990s with (1).jpg)
Genzyme 
Novartis AG .jpg)
While this isn’t a .jpg)
The holiday season is officially over and its time to face the prospects of a new year! The good news is that the economy is recovering and new job opportunities are beginning to appear at an increasing rate. To that end, it may be a good time to re-evaluate your career options and fine tune every element of your ongoing job search. The most obvious activities include updating your resume (assuming that things have changed since 2009), resuming your networking activities and looking online for new job prospects. However, Phyllis Korkki, a New York Times career columnist, 